SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zoetis Inc. - ZTS
NEW YORK , May 16, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or the "Company") (NYSE: ZTS). Such investors are advised to contact Da...
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zoetis Inc. and Encourages Investors with Losses to Cont...
LOS ANGELES, CA / ACCESSWIRE / May 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Z...
Is Trending Stock Zoetis Inc. (ZTS) a Buy Now?
Zacks.com users have recently been watching Zoetis (ZTS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Zoetis: Long-Term Buy Despite Safety Concerns
Zoetis is a leader in animal health, focusing on R&D to develop innovative medicines and technologies for pets and livestock. Concerns have arisen about the safety of their drugs, but Zoetis appear...
Zoetis (ZTS) Q1 Earnings and Revenues Surpass Estimates
Zoetis (ZTS) reports better-than-expected first-quarter results, wherein both earnings and revenues beat estimates. Shares rise.
Compared to Estimates, Zoetis (ZTS) Q1 Earnings: A Look at Key Metrics
The headline numbers for Zoetis (ZTS) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimat...
Zoetis (ZTS) Beats Q1 Earnings and Revenue Estimates
Zoetis (ZTS) came out with quarterly earnings of $1.38 per share, beating the Zacks Consensus Estimate of $1.34 per share. This compares to earnings of $1.31 per share a year ago.
Zoetis beats profit estimates on strong demand for pet products
Animal healthcare company Zoetis surpassed analysts' expectations for first-quarter profit on Thursday, helped by strong demand for its medicines and vaccines for pets.
Unveiling Zoetis (ZTS) Q1 Outlook: Wall Street Estimates for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Zoetis (ZTS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the q...
Wall Street Analysts Look Bullish on Zoetis (ZTS): Should You Buy?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) an...
Zoetis (ZTS) Stock Dips While Market Gains: Key Facts
In the latest trading session, Zoetis (ZTS) closed at $145.54, marking a -0.66% move from the previous day.
Despite Lawsuit Risks: Why Zoetis Remains A Compelling Investment
Zoetis Inc. has seen a significant decline in its stock price, dropping more than 24% since January. The decline is partly due to market weakness and the ongoing growth to value rotation, as well a...
Zoetis shares drop amid concerns over arthritis shots' safety for pets
Zoetis Inc (NYSE:ZTS, ETR:ZOE) shares took a hit Friday after a Wall Street Journal report that suggested the company's arthritis shots may have sickened dogs and cats. The arthritis shots, Librela...
Zoetis Stock Falls on Concerns Over Pet Arthritis Drugs. Company Says They're Safe.
An article in The Wall Street Journal highlights the scrutiny over the company's arthritis treatments for pets.
Related Companies